JP2024531799A5 - - Google Patents
Info
- Publication number
- JP2024531799A5 JP2024531799A5 JP2024517163A JP2024517163A JP2024531799A5 JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5 JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- decitabine
- effective amount
- sedazulidine
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246547P | 2021-09-21 | 2021-09-21 | |
| US63/246,547 | 2021-09-21 | ||
| PCT/US2022/076757 WO2023049731A2 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531799A JP2024531799A (ja) | 2024-08-29 |
| JP2024531799A5 true JP2024531799A5 (cg-RX-API-DMAC7.html) | 2025-09-30 |
Family
ID=85721229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517163A Pending JP2024531799A (ja) | 2021-09-21 | 2022-09-21 | 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000888A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4404940A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531799A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240064656A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118201622A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022348907B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232623A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003537A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202327625A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023049731A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| AU2024265282A1 (en) * | 2023-05-02 | 2025-12-18 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708264C (en) * | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| US10683552B2 (en) * | 2014-11-25 | 2020-06-16 | Presidents And Fellows Of Harvard College | Clonal haematopoiesis |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| WO2021113688A1 (en) * | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
| EP4090335A1 (en) * | 2020-01-17 | 2022-11-23 | Novartis AG | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-09-21 MX MX2024003537A patent/MX2024003537A/es unknown
- 2022-09-21 AU AU2022348907A patent/AU2022348907B2/en active Active
- 2022-09-21 US US18/693,727 patent/US20250000888A1/en active Pending
- 2022-09-21 CN CN202280073476.0A patent/CN118201622A/zh active Pending
- 2022-09-21 EP EP22873816.7A patent/EP4404940A4/en active Pending
- 2022-09-21 CA CA3232623A patent/CA3232623A1/en active Pending
- 2022-09-21 TW TW111135794A patent/TW202327625A/zh unknown
- 2022-09-21 WO PCT/US2022/076757 patent/WO2023049731A2/en not_active Ceased
- 2022-09-21 KR KR1020247010215A patent/KR20240064656A/ko active Pending
- 2022-09-21 JP JP2024517163A patent/JP2024531799A/ja active Pending